Diaceutics PLC (DXRX) - Net Assets
Based on the latest financial reports, Diaceutics PLC (DXRX) has net assets worth GBX37.24 Million GBX (≈ $4.53K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX44.42 Million ≈ $5.40K USD) and total liabilities (GBX7.18 Million ≈ $873.84 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read DXRX total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX37.24 Million |
| % of Total Assets | 83.83% |
| Annual Growth Rate | 83.75% |
| 5-Year Change | -0.95% |
| 10-Year Change | N/A |
| Growth Volatility | 236.23 |
Diaceutics PLC - Net Assets Trend (2015–2024)
This chart illustrates how Diaceutics PLC's net assets have evolved over time, based on quarterly financial data. Also explore how large is Diaceutics PLC's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Diaceutics PLC (2015–2024)
The table below shows the annual net assets of Diaceutics PLC from 2015 to 2024. For live valuation and market cap data, see Diaceutics PLC market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX39.86 Million ≈ $4.85K |
-2.28% |
| 2023-12-31 | GBX40.79 Million ≈ $4.96K |
-4.06% |
| 2022-12-31 | GBX42.51 Million ≈ $5.17K |
+4.59% |
| 2021-12-31 | GBX40.65 Million ≈ $4.95K |
+1.02% |
| 2020-12-31 | GBX40.24 Million ≈ $4.90K |
+99.87% |
| 2019-12-31 | GBX20.13 Million ≈ $2.45K |
+665.64% |
| 2018-12-31 | GBX2.63 Million ≈ $319.93 |
+40.03% |
| 2017-12-31 | GBX1.88 Million ≈ $228.47 |
+85.50% |
| 2016-12-31 | GBX1.01 Million ≈ $123.16 |
+507.18% |
| 2015-12-31 | GBX166.71K ≈ $20.28 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diaceutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4066731200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX40.62 Million | 101.93% |
| Common Stock | GBX170.00K | 0.43% |
| Other Comprehensive Income | GBX-626.00K | -1.57% |
| Total Equity | GBX39.86 Million | 100.00% |
Diaceutics PLC Competitors by Market Cap
The table below lists competitors of Diaceutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
$1.71 Million |
|
Dotdigital Group Plc
LSE:DOTD
|
$1.71 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:TASDA
|
$1.71 Million |
|
Doric Nimrod Air Three Ltd
LSE:DNA3
|
$1.71 Million |
|
Bank Pembangunan Daerah Banten Tbk PT
JK:BEKS
|
$1.70 Million |
|
Usha Martin Education & Solutions Limited
NSE:UMESLTD
|
$1.70 Million |
|
Chinhung International Inc. Pfd. Series 2
KO:002787
|
$1.70 Million |
|
Cambium Networks Corp
NASDAQ:CMBM
|
$1.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diaceutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,786,000 to 39,857,000, a change of -929,000 (-2.3%).
- Net loss of 1,703,000 reduced equity.
- New share issuances of 136,000 increased equity.
- Other comprehensive income decreased equity by 386,000.
- Other factors increased equity by 1,024,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.70 Million | -4.27% |
| Share Issuances | GBX136.00K | +0.34% |
| Other Comprehensive Income | GBX-386.00K | -0.97% |
| Other Changes | GBX1.02 Million | +2.57% |
| Total Change | GBX- | -2.28% |
Book Value vs Market Value Analysis
This analysis compares Diaceutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 350.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26783.85x to 350.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | GBX0.01 | GBX165.50 | x |
| 2016-12-31 | GBX0.01 | GBX165.50 | x |
| 2017-12-31 | GBX0.03 | GBX165.50 | x |
| 2018-12-31 | GBX0.04 | GBX165.50 | x |
| 2019-12-31 | GBX0.31 | GBX165.50 | x |
| 2020-12-31 | GBX0.52 | GBX165.50 | x |
| 2021-12-31 | GBX0.48 | GBX165.50 | x |
| 2022-12-31 | GBX0.49 | GBX165.50 | x |
| 2023-12-31 | GBX0.48 | GBX165.50 | x |
| 2024-12-31 | GBX0.47 | GBX165.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diaceutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.30%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.22x
- Recent ROE (-4.27%) is below the historical average (6.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -62.08% | -7.40% | 1.04x | 8.05x | GBX-120.16K |
| 2016 | 73.81% | 16.28% | 1.33x | 3.40x | GBX645.91K |
| 2017 | 35.32% | 9.00% | 1.34x | 2.92x | GBX475.42K |
| 2018 | 24.05% | 6.10% | 1.33x | 2.97x | GBX369.36K |
| 2019 | 1.98% | 2.96% | 0.60x | 1.11x | GBX-1.62 Million |
| 2020 | 0.65% | 2.07% | 0.29x | 1.08x | GBX-3.76 Million |
| 2021 | 1.38% | 4.02% | 0.31x | 1.11x | GBX-3.50 Million |
| 2022 | 1.70% | 3.71% | 0.40x | 1.14x | GBX-3.53 Million |
| 2023 | -4.28% | -7.37% | 0.51x | 1.14x | GBX-5.82 Million |
| 2024 | -4.27% | -5.30% | 0.66x | 1.22x | GBX-5.69 Million |
Industry Comparison
This section compares Diaceutics PLC's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $32,090,082
- Average return on equity (ROE) among peers: -29.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diaceutics PLC (DXRX) | GBX37.24 Million | -62.08% | 0.19x | $1.70 Million |
| Cambridge Cognition Holdings Plc (COG) | $3.36 Million | -53.09% | 2.88x | $201.09K |
| Craneware Plc (CRW) | $32.41 Million | 18.56% | 0.77x | $6.59 Million |
| Feedback PLC (FDBK) | $1.20 Million | -39.29% | 0.61x | $51.98K |
| Induction Healthcare Group PLC (INHC) | $-2.64 Million | 0.00% | 0.00x | $111.33K |
| IQ-AI Ltd (IQAI) | $590.00K | -47.63% | 0.17x | $24.76K |
| Kooth plc (KOO) | $10.52 Million | -6.81% | 0.53x | $563.19K |
| Optima Health plc (OPT) | $168.12 Million | 0.98% | 0.30x | $2.04 Million |
| Renalytix AI plc (RENX) | $43.17 Million | -104.88% | 0.47x | $95.71K |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more